DOCSLIB.ORG

( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2020/0215078 A1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2020/0215078 A1 US 20200215078A1 IN (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No .: US 2020/0215078 A1 ROGAWSKI et al. (43 ) Pub . Date : Jul. 9 , 2020 (54 ) MITIGATION OF EPILEPTIC SEIZURES BY Publication Classification COMBINATION THERAPY USING (51 ) Int. Ci. BENZODIAZEPINES AND NEUROSTEROIDS A61K 31/57 (2006.01 ) A61K 45/06 (2006.01 ) ( 71) Applicant: The Regents of the University of A61P 25/08 ( 2006.01 ) California , Oakland , CA (US ) A61K 31/439 (2006.01 ) ( 72 ) Inventors : Michael A. ROGAWSKI, Sacramento , A61K 31/5513 ( 2006.01) CA (US ) ; Isaac N. PESSAH , Davis , A61K 31/5517 (2006.01 ) CA (US ) ; Zhengyu CAO , Woodland , (52 ) U.S. CI. CA (US ) ; Pamela J. LEIN , Davis , CA CPC A61K 31/57 ( 2013.01 ) ; A61K 45/06 (US ) (2013.01 ) ; A61K 31/5517 ( 2013.01 ) ; A61K 31/439 (2013.01 ) ; A61K 31/5513 ( 2013.01 ) ; ( 21) Appl. No .: 16 /544,480 A61P 25/08 (2018.01 ) Aug. 19 , 2019 ( 22 ) Filed : (57 ) ABSTRACT Related U.S. Application Data Provided are compositions comprising a benzodiazepine and (63 ) Continuation of application No. 15 /649,460 , filed on a neurosteroid , containing one or both of the benzodiazepine Jul. 13 , 2017 , now Pat . No. 10,426,786 , which is a and the neurosteroid in a subtherapeutic dose , and admin continuation of application No. 13 / 964,922 , filed on istration of such compositions for mitigation of an epileptic Aug. 12 , 2013 , now abandoned . seizure . Further provided are compositions comprising a (60 ) Provisional application No. 61 /798,094 , filed on Mar. benzodiazepine, a neurosteroid , and an NMDA blocker, and 15 , 2013 , provisional application No. 61/ 682,745 , administration of such compositions for mitigation of an filed on Aug. 13 , 2012 . epileptic seizure . Patent Application Publication Jul 9 ,? 2020 Sheet 1 of 25 US2020 / 0215078A1 Vehicle / TETS ???????? ????? ?? ???? conhecimentos están base Vehicle ?? ?? ??????????? ????? ?????????? ?????????? ???????? || ?????????? 3iN ??????? ||||| n 300 Phase 1 FIG . 1A Patent Application Publication Jul. 9 , 2020 Sheet 2 of 25 US 2020/0215078 A1 70 046 Log [ TETSJ M FIG . 1B FIG . 1C Patent Application Publication Jul. 9 , 2020 Sheet 3 of 25 US 2020/0215078 A1 V FIG . 1D T Phase Il response Washout Vehicle TETS ( 3 UM ) milione un Amenn 500AFU ad all 500 S FIG . 2 Patent Application Publication Jul 9 ,? 2020 Sheet 4 of 25 US2020 / 0215078A1 ??????????????? ????? ) 3 ?? M ( 100 ? M ( FIG . 3A Patent Application Publication Jul. 9 , 2020 Sheet 5 of 25 US 2020/0215078 A1 Phase 1 Fluo-4fluorescenceunits AUC)( dah FIG . 3B Phase II- Frequency Caktoscillations/10min FIG . 3C Patent Application Publication Jul. 9 , 2020 Sheet 6 of 25 US 2020/0215078 A1 Phase II- Amplitude Caktoscillationsamplitude (AF/F) . FIG . 3D Patent Application Publication Jul. 9 , 2020 Sheet 7 of 25 US 2020/0215078 A1 *** M TETS (0.23M ) WY w w 14 3 TETS (64M ) E wwwwwww FIG . 4A Spikefrequency(spikes/s) ??? 6 Basal 8 6 Log [ TETS ) M FIG . 4B Patent Application Publication Jul. 9 , 2020 Sheet 8 of 25 US 2020/0215078 A1 32 3.50 non potuit la tarde FIG . 5A 32 3.96 FIG . 5B Patent Application Publication Jul. 9 ,? 2020 Sheet 9 of 25 US2020 / 0215078A1 ????? ???? ?????? ??? ??????? ??????? ????????? * TETS (3M ) FIG . 6A Patent Application Publication Jul. 9 , 2020 Sheet 10 of 25 US 2020/0215078 A1 Fluo-4fluorescenceunits FIG . 6B Phase II- Frequency Ca2+oscillations/10min FIG . 6C Patent Application Publication Jul. 9 , 2020 Sheet 11 of 25 US 2020/0215078 A1 Phase 11- Amplitude Cal*oscillationsamplitude OF)/F( FIG . 6D Patent Application Publication Jul. 9 , 2020 Sheet 12 of 25 US 2020/0215078 A1 or DZP or TETS ????? ??? ????????? ??????? ??????? w TETS (3M ) DZP (0.03M ) will + TETS (3M ) ?????? ???? DZP (0.1M ) TETS (3uM ) will ull DZPDZP( (0.3M 0.34M ) whe * TET ( 3uM ) DZP (1M ) whanh * TETS ( 3uM ) FIG . 7A Patent Application Publication Jul. 9 , 2020 Sheet 13 of 25 US 2020/0215078 A1 Phase 1 ** Fluo-fluorescence4units Onv) DZP ( UM ) + TETS FIG . 7B Phase II- Frequency Caltoscillations/10min 0.3 DZP (UM ) + TETS FIG . 70 Patent Application Publication Jul. 9 , 2020 Sheet 14 of 25 US 2020/0215078 A1 Phase Il -Amplitude 38 Ca2+oscillationsamplitude (AF/F) ** 0.03 0.3 1 FIG . 7D Patent Application Publication Jul 9 ,? 2020 Sheet 15 of 25 US2020 / 0215078 Al www.lankan melewin | | | ???????? ???? ????? ???? || (11 / ?????? ????????? ??????? FIG . 8A Patent Application Publication Jul. 9 , 2020 Sheet 16 of 25 US 2020/0215078 A1 Phase I Fluo-fluorescence4units (AUC) AlloP (HMUM ) ) * TETESTETES FIG , 8B Phase Il- Frequency 30 20 oscillations/10minCalt IS 10 AlloP ( MOM )+ * TETES FIG . 8C Patent Application Publication Jul. 9 , 2020 Sheet 17 of 25 US 2020/0215078 A1 Phase Il -Amplitude Caltoscillationsamplitude la : 0.03 AlloP ( M ) * TETES FIG . 8D Patent Application Publication Jul 9 ,? 2020 Sheet 18 of 25 US2020 / 0215078 Al ??????? ?????? FIF ?????????? ?????????? FIG . 9A Patent Application Publication Jul. 9 , 2020 Sheet 19 of 25 US 2020/0215078 A1 Phasel . : . : . IN Fluo-4fluorescenceunits (AUC,%Control) 0 * DZP FIG . 9B Phase II- Frequency Caltoscillationsamplitude Control)(% 60 FIG . 9C Patent Application Publication Jul 9 ,? 2020 Sheet 20 of 25 US2020 / 0215078 Al Phase Il- Frequency ?? Ca2+oscillationsamplitude (%Control) TETS Allop DZP + AlloP + OZP FIG . 9D ?????? ?? ?? ??????? Veh ???????? TETS) 38 ( ???? ?????? ??????? TETS +A ???? ????????? TETS+ 0 ???? ???? ?? ????? ???? ?? ?? FIG . 10A Patent Application Publication Jul. 9 , 2020 Sheet 21 of 25 US 2020/0215078 A1 30 p < 0.01 p < 0.01 Ca*oscillations/10min TETS TETS + A TETS + DTETS + A + D FIG . 10B 1.2 p < 0.01 p< 0.01 , p< 0.01 Amplitude(AF/FO) TETS TETS +ATETS + DTETS + A + D FIG . 10C Patent Application Publication Jul. 9 , 2020 Sheet 22 of 25 US 2020/0215078 A1 TETS Average Time to Onset 36 43Suun 16 S T + TETS monic SoiZe 27 S + r. NO ...2 TETS + Diazepam TETS clonic semua diazepam ( 5 mg/ kg , ip ) . .* wit CARA .14* . **??????? ??????? FIG . 11 Patent Application Publication Jul. 9 , 2020 Sheet 23 of 25 US 2020/0215078 A1 FIG.12 Patent Application Publication Jul. 9 , 2020 Sheet 24 of 25 US 2020/0215078 A1 u 300 2.im FIG.13 Patent Application Publication Jul. 9 , 2020 Sheet 25 of 25 US 2020/0215078 A1 Inject mice Begin blood Mouse Blood Pressure DiastolicAverage BloodPressure 0.03 mg /kg DZP 0.03mg/ kg Allop 5mg/ kg DZP FIG . 14 US 2020/0215078 A1 Jul. 9. 2020 1 MITIGATION OF EPILEPTIC SEIZURES BY pentylenetetrazol. Limited cellular physiological studies and COMBINATION THERAPY USING results from [ SS ] t- butylbicyclophosphorothionate binding BENZODIAZEPINES AND NEUROSTEROIDS to brain membranes indicate that TETS inhibits GABA , receptors with an IC50 in the range of 1 uM (Squires et al , CROSS - REFERENCE TO RELATED 1983 ; Esser et al, 1991 ; Ratra et al. , 2001 ) and it is therefore APPLICATIONS comparable in potency to picrotoxin as an inhibitor of GABA , receptors (Squires et al. , 1983; Cole and Casida, [0001 ] This application is a continuation of U.S. applica 1986 , Ratra et al, 2001 ) . tion Ser. No. 13/ 964,922, filed on Aug. 12 , 2013 , which [ 0007 ] Cultured hippocampal neurons display synchro claims the benefit under 35 U.S.C. § 119 ( e ) of U.S. Provi nous spontaneous Ca2 + oscillations ( Tanaka et al, 1996 ) that sional Application No. 61 /682,745 filed on Aug. 13 , 2012 are driven by action potential- dependent synaptic transmis and U.S. Provisional Application No. 61/ 798,094 filed on sion Disruption of Ca2 + oscillations by environmental toxi Mar. 15 , 2013 , all of which are hereby incorporated herein cants has been reported (Soria -Mercado et al ., 2009 ; Cao et by reference in their entireties for all purposes . al , 2010 , Choi et al, 2010 , Percira et al. , 2010 , Cao et al ., STATEMENT OF GOVERNMENTAL SUPPORT 2011 ). Hippocampal neurons also exhibit spontaneous elec trical discharges as they form functional neuronal networks . [ 0002 ] This invention was made with Government support These discharges , as detected in extracellular recordings , under Grant Nos . AG032119 , NS072094 , and NS079202 consist of infrequent synchronized field potentials , mixed awarded by the National institutes of Health . The Govern with more frequent desynchronized random action poten ment has certain rights in this invention . tials (Cao et al. , 2012 ; Frega et al. , 2012 ) . Synchronous Ca2- oscillations and neuronal electrical firing co -occur FIELD ( Jimbo et al. , 1993) and are important in mediating neuronal [0003 ] Provided are compositions comprising a benzodi development and activity dependent dendritic growth (Way azepine and a neurosteroid , containing one or both of the man et al . , 2008 ) Genetic or environmental factors that benzodiazepine and the neurosteroid in a subtherapeutic interfere with neuronal transmission influence the overall dose , and administration of such compositions for mitigation neuronal networks activity (Kenet et al. , 2007, Meyer et al. , of an epileptic seizure . Further provided are compositions 2008 ; Shafer et al ., 2008 ; Frega et al. , 2012 ; Wayman et al. , comprising a benzodiazepine, a neurosteroid , and an NMDA 2012 ). For example picrotoxin , a GABA , receptor antago blocker, and administration of such compositions for miti nist, produces striking changes in network electric activity gation of an epileptic seizure . (Cao et al. , 2012 ; Frega et al. , 2012 ) . Diisopropylfluoro phosphate , an irreversible inhibitor of cholinesterase has BACKGROUND also been shown to elicit status epileptics in rats . Hippocam pal neurons
Load more

Recommended publications
  • Docteur» at the University François Rabela
    UNIVERSITÉ FRANÇOIS – RABELAIS DE TOURS École Doctorale « Santé - Sciences Biologiques - Chimie du Vivant » and UNIVERSITY OF LJUBLJANA, FACULTY OF PHARMACY «Department of Pharmaceutical Chemistry» A cotutelle thesis submitted in fulfillment of the requirements for the degree of «Docteur» at the University François Rabelais of Tours (France) and Doctor of Pharmacy at the University of Ljubljana (Slovenia) In Pharmaceutical Chemistry Publicly defended on the 1st of March 2013 by Mitja KOVAČ in Ljubljana FLUORATION DE DERIVES DU BENZOVESAMICOL POUR L'OBTENTION DE RADIOLIGANDS POTENTIELS DU TRANSPORTEUR VESICULAIRE DE L'ACETYLCHOLINE Under the co-direction of: Associate Professor Sylvie Mavel (MCU, Tours) and Associate Professor Marko Anderluh (Ljubljana) ----------------- JURY for Oral Defense: Ms MAVEL Sylvie – Associate Professor, University François-Rabelais, Tours, France Mr ANDERLUH Marko – Associate Professor, University of Ljubljana, Slovenia Mr DOLLÉ Frédéric – Service Hospitalier Frédéric Joliot, Institut d'Imagerie BioMédicale - CEA, Orsay, France (Reviewer) Mr EMOND Patrick – Professor, University François-Rabelais, Tours, France Ms GMEINER STOPAR Tanja – Assistant Professor, University of Ljubljana, Slovenia (Reviewer) Mr GOBEC Stanislav – Professor, University of Ljubljana, Slovenia (Chairman) This cotutelle PhD was carried out with the collaboration between the University of Tours (Laboratoire de Biophysique Médicale et Pharmaceutique, Unité INSERM U930 - FRANCE) and the University of Ljubljana (Faculty of Pharmacy, Department of Pharmacutical Chemistry - SLOVENIA). The work was supported by a grant from the Slovene Human Resources Development and Scholarship Fund, by a grant from the University of Ljubljana (Inovativna shema za sofinanciranje doktorskega študija za spodbujanje sodelovanja z gospodarstvom in reševanja aktualnih družbenih izzivov - generacija 2010 Univerza v Ljubljani), and by a Slovenia- French bilateral collaboration project (project n° BI-FR/12-13-PROTEUS-007).
    [Show full text]
  • WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 498/04 (2006.01) A61K 31/5365 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 519/00 (2006.01) A61P 25/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/IB20 17/050844 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 15 February 2017 (15.02.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/298,657 23 February 2016 (23.02.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, New York, New York 10017 (US).
    [Show full text]
  • Ketamine As a Novel Treatment for Major Depressive Disorder and Bipolar Depression: a Systematic Review and Quantitative Meta-Analysis☆
    General Hospital Psychiatry 37 (2015) 178–184 Contents lists available at ScienceDirect General Hospital Psychiatry journal homepage: http://www.ghpjournal.com Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis☆ Ellen E. Lee, M.D., Megan P. Della Selva, M.D., Anson Liu, M.D., Seth Himelhoch, M.D., M.P.H. ⁎ Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD article info abstract Article history: Objective: Given the significant disability, morbidity and mortality associated with depression, the promising Received 9 September 2014 recent trials of ketamine highlight a novel intervention. A meta-analysis was conducted to assess the efficacy Revised 29 December 2014 of ketamine in comparison with placebo for the reduction of depressive symptoms in patients who meet criteria Accepted 8 January 2015 for a major depressive episode. Method: Two electronic databases were searched in September 2013 for English-language studies that were ran- Keywords: domized placebo-controlled trials of ketamine treatment for patients with major depressive disorder or bipolar Ketamine Depression depression and utilized a standardized rating scale. Studies including participants receiving electroconvulsive ther- Therapy apy and adolescent/child participants were excluded. Five studies were included in the quantitative meta-analysis. Meta-analysis Results: The quantitative meta-analysis showed that ketamine significantly reduced depressive symptoms. The overall effect size at day 1 was large and statistically significant with an overall standardized mean difference of 1.01 (95% confidence interval 0.69–1.34) (Pb.001), with the effects sustained at 7 days postinfusion. The heteroge- neity of the studies was low and not statistically significant, and the funnel plot showed no publication bias.
    [Show full text]
  • Toxicity Equivalence Factors for Marine Biotoxins Associated with Bivalve Molluscs TECHNICAL PAPER
    JOINT FAO/WHO Toxicity Equivalency Factors for Marine Biotoxins Associated with Bivalve Molluscs TECHNICAL PAPER Cover photograph: © FAOemergencies JOINT FAO/WHO Toxicity equivalence factors for marine biotoxins associated with bivalve molluscs TECHNICAL PAPER FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS WORLD HEALTH ORGANIZATION ROME, 2016 Recommended citation: FAO/WHO. 2016. Technical paper on Toxicity Equivalency Factors for Marine Biotoxins Associated with Bivalve Molluscs. Rome. 108 pp. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Food and Agriculture Organization of the United Nations (FAO) or of the World Health Organization (WHO) concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or products of manufacturers, whether or not these have been patented, does not imply that these are or have been endorsed or recommended by FAO or WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by FAO and WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall FAO and WHO be liable for damages arising from its use.
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • Environmental Properties of Chemicals Volume 2
    1 t ENVIRONMENTAL 1 PROTECTION Esa Nikunen . Riitta Leinonen Birgit Kemiläinen • Arto Kultamaa Environmental properties of chemicals Volume 2 1 O O O O O O O O OO O OOOOOO Ol OIOOO FINNISH ENVIRONMENT INSTITUTE • EDITA Esa Nikunen e Riitta Leinonen Birgit Kemiläinen • Arto Kultamaa Environmental properties of chemicals Volume 2 HELSINKI 1000 OlO 00000001 00000000000000000 Th/s is a second revfsed version of Environmental Properties of Chemica/s, published by VAPK-Pub/ishing and Ministry of Environment, Environmental Protection Department as Research Report 91, 1990. The pubiication is also available as a CD ROM version: EnviChem 2.0, a PC database runniny under Windows operating systems. ISBN 951-7-2967-2 (publisher) ISBN 952-7 1-0670-0 (co-publisher) ISSN 1238-8602 Layout: Pikseri Julkaisupalvelut Cover illustration: Jussi Hirvi Edita Ltd. Helsinki 2000 Environmental properties of chemicals Volume 2 _____ _____________________________________________________ Contents . VOLUME ONE 1 Contents of the report 2 Environmental properties of chemicals 3 Abbreviations and explanations 7 3.1 Ways of exposure 7 3.2 Exposed species 7 3.3 Fffects________________________________ 7 3.4 Length of exposure 7 3.5 Odour thresholds 8 3.6 Toxicity endpoints 9 3.7 Other abbreviations 9 4 Listofexposedspecies 10 4.1 Mammais 10 4.2 Plants 13 4.3 Birds 14 4.4 Insects 17 4.5 Fishes 1$ 4.6 Mollusca 22 4.7 Crustaceans 23 4.8 Algae 24 4.9 Others 25 5 References 27 Index 1 List of chemicals in alphabetical order - 169 Index II List of chemicals in CAS-number order
    [Show full text]
  • Cerebellar Toxicity of Phencyclidine
    The Journal of Neuroscience, March 1995, 75(3): 2097-2108 Cerebellar Toxicity of Phencyclidine Riitta N&kki, Jari Koistinaho, Frank Ft. Sharp, and Stephen M. Sagar Department of Neurology, University of California, and Veterans Affairs Medical Center, San Francisco, California 94121 Phencyclidine (PCP), clizocilpine maleate (MK801), and oth- Phencyclidine (PCP), dizocilpine maleate (MK801), and other er NMDA antagonists are toxic to neurons in the posterior NMDA receptor antagonistshave attracted increasing attention cingulate and retrosplenial cortex. To determine if addition- becauseof their therapeutic potential. These drugs have neuro- al neurons are damaged, the distribution of microglial ac- protective properties in animal studies of focal brain ischemia, tivation and 70 kDa heat shock protein (HSP70) induction where excitotoxicity is proposedto be an important mechanism was studied following the administration of PCP and of neuronal cell death (Dalkara et al., 1990; Martinez-Arizala et MK801 to rats. PCP (10-50 mg/kg) induced microglial ac- al., 1990). Moreover, NMDA antagonists decrease neuronal tivation and neuronal HSP70 mRNA and protein expression damage and dysfunction in other pathological conditions, in- in the posterior cingulate and retrosplenial cortex. In ad- cluding hypoglycemia (Nellgard and Wieloch, 1992) and pro- dition, coronal sections of the cerebellar vermis of PCP (50 longed seizures(Church and Lodge, 1990; Faingold et al., 1993). mg/kg) treated rats contained vertical stripes of activated However, NMDA antagonists are toxic to certain neuronal microglial in the molecular layer. In the sagittal plane, the populations in the brain. Olney et al. (1989) demonstratedthat microglial activation occurred in irregularly shaped patch- the noncompetitive NMDA antagonists,PCP, MK801, and ke- es, suggesting damage to Purkinje cells.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Self-Administration of Abused Substances: Methods for Study
    Self-Administration of Abused Substances: Methods for Study U.S. DEPARTMENT OF HEALTH, EDUCATION AND WELFARE Public Health Service Alcohol, Drug Abuse, and Mental Health Administration Self-Administration of Abused Substances: Methods for Study Editor: Norman A. Krasnegor, Ph.D. NIDA Research Monograph 20 July 1978 DEPARTMENT OF HEALTH. EDUCATION, AND WELFARE Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents U.S. Government Printing Office, Washington, D.C. 20402 Stock No. 017-024-00794-3 The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical re- views of research problem areas and techniques, the content of state-of-the-art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Polo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California William McGlothlin, Ph.D. Department of Psychology. UCLA Los Angeles, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education, DHEW Washington, D C Lee Robins, Ph.D. Washington University School of Medicine St Louis, Missouri NIDA Research Monograph series William Pollin, M.D.
    [Show full text]
  • Design & Synthesis of Polycyclic Amine Derivatives for Sigma Receptor Activity
    UNIVERSITY OF THE WESTERN CAPE Design & Synthesis of Polycyclic Amine derivatives for Sigma Receptor Activity Natasha Strydom February 2013 Supervisor: Prof. S.F. Malan Co-Supervisor: Dr. J. Joubert A thesis submitted in partial fulfilment of the requirements for the degree of Magister Scientiae in the Department of Natural Sciences, University of the Western Cape. KEYWORDS Polycyclic amine Pentacycloundecane Amantadine Heterocyclic amines Sigma receptor Neurodegeneration Drug addiction Blood brain permeability Drug Design Ligand based Structure activity relationship i ABSTRACT New therapeutic strategies are needed for a diverse array of poorly understood neurological impairments. These include neurodegenerative disorders such as Parkinson’s disease and Alzheimer’s disease, and the psychiatric disorders such as depression, anxiety and drug dependence. Popular neuropharmacotherapies have focused on dopamine (DA), serotonin (5HT), γ-aminobutric acid (GABA) and glutamate systems (Jupp & Lawrence, 2010). However recent research points to the sigma receptor (σR) as a possible neuromodulatory system. Due to its multi-receptor action, the σR can trigger several significant biological pathways. This indicates its ideal potential as a drug target to effectively minimise drug dosage and potential side effects. Currently there are a limited number of σR ligands available and few possess the selectivity to significantly show σR’s role in neurological processes. Polycyclic amines have shown notable sigma activity and provide an advantageous scaffold for drug design that can improve pharmacodynamic and pharmacokinetic properties (Banister et al., 2010; Geldenhuys et al., 2005). Aryl-heterocycle amine groups were also shown to improve σR activity (Piergentili et al., 2009). A series of pentacycloundecane compounds were synthesised which aimed at evaluating the inclusion of a amine containing aryl group in the design compared to previous pentacycloundecane structures containing only two lipophilic regions.
    [Show full text]
  • Guide No. 1 – October 2020 2/12 the CONCEPT and IMPLEMENTATION of CPA GUIDANCE RESIDUE LEVELS
    Cooperation Centre for Scientific Research Relative to Tobacco CORESTA GUIDE N° 1 The Concept and Implementation of CPA Guidance Residue Levels October 2020 Agro-Chemical Advisory Committee CORESTA TECHNICAL GUIDE N° 1 Title: The Concept and Implementation of CPA Guidance Residue Levels Status: Valid Note: This document will be periodically reviewed by CORESTA Document history: Date of review Information July 2003 Version 1 GRL for Pyrethrins () and Terbufos corrected. December 2003 CPA terminology corrected. June 2008 Version 2 – GRLs revised and residue definitions added Provisional GRL of 2.00 ppm for Cyfluthrin to replace previous June 2010 GRL of 0.50 ppm July 2013 Version 3 – GRLs revised October 2013 Note for Maleic Hydrazide revised Version 4 – GRLs revised + clarification that scope of GRLs July 2016 applies predominantly to the production of traditional cigarette tobaccos and GAP associated with their cultivation. June 2018 Fluopyram GRL of 5 ppm added to GRL list Version 5 – Nine new CPAs with GRL added to list. November 2019 Revision of GRLs for Chlorantraniliprole and Indoxacarb. Updated web links. October 2020 Version 6 – Flupyradifurone GRL of 21 ppm added to GRL list. CORESTA Guide No. 1 – October 2020 2/12 THE CONCEPT AND IMPLEMENTATION OF CPA GUIDANCE RESIDUE LEVELS Executive Summary • Guidance Residue Levels (GRLs) are in the remit of the Agro-Chemical Advisory Committee (ACAC) of CORESTA. Their development is a joint activity of all ACAC members, who represent the leaf production, processing and manufacturing sectors of the Tobacco Industry. The concept of GRLs and their implementation are described in this guide. • GRLs provide guidance to tobacco growers and assist with interpretation and evaluation of results from analyses of residues of Crop Protection Agents (CPAs*).
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]